Shorya Awtar's Parallel Robotics discloses $7.3M for handheld surgical robotics

Why it matters

Parallel Robotics has paired an FDA-cleared handheld laparoscopic device with licensed university intellectual property, a $305,000 NSF award and $7.31M in securities sold. It now has to prove that surgeons and hospitals will adopt MediBot.

University of Michigan professor Shorya Awtar has disclosed $7.31 million in securities sold by Parallel Robotics, according to a Form D filed with the SEC on September 21st. The Ann Arbor surgical-device developer is seeking $11.31 million in total, leaving roughly $4 million of the offering open.

The filing records $7.31 million in capital sold to date by Parallel Robotics. A Michigan Strategic Fund annual report separately lists Parallel Robotics LLC in connection with a $250,000 convertible-debt transaction dated October 4th, 2024.

Awtar's interest in affordable surgical tools grew from two encounters with open surgery. His mother underwent an open hysterectomy in India, and his wife later received an open emergency appendectomy in the United States. Awtar, who was working at GE Global Research at the time, had also seen an early surgical robot and was struck by its price. He left industry, joined the University of Michigan faculty in 2007 and began building alternatives.

That work made Awtar a founder before Parallel Robotics. University of Michigan Innovation Partnerships says Awtar and surgeon James Geiger joined medical-device entrepreneur Greg Bowles to create FlexDex Surgical, which developed an articulating laparoscopic needle driver designed to reproduce wrist-like movement through a mechanical instrument. Michigan Engineering reported that Awtar was elected to the National Academy of Engineering in 2023 for his work on making minimally invasive surgery affordable and accessible.

A powered turn in Awtar's low-cost thesis

Parallel Robotics marks an evolution in Awtar's engineering approach. FlexDex's needle driver required no power source and launched with a $500 price in 2017. Parallel Robotics' MediBot Needle Driver Uno adds electronics, software and a separate control box while preserving direct, bedside operation by the surgeon.

The FDA cleared MediBot on May 24th as a Class II laparoscopic device. MediBot is a single-use instrument for suturing and knot-tying during minimally invasive abdominal procedures. The surgeon moves the handle at the wrist to articulate the jaws, turns a dial to rotate them and squeezes a trigger to grasp a needle or suture.

A cable links the handpiece to a control box that supplies power and computation. The design gives Parallel Robotics a middle position between rigid manual instruments and full surgical systems with consoles and patient-side carts. An NSF award description calls the underlying approach a blend of human power and computer control, with the surgeon retaining tactile, bedside command of the instrument.

The FDA based its clearance on substantial equivalence to Human Extensions' HandX device and on non-clinical testing covering mechanical performance, software, electrical safety, sterilization and simulated use. The regulatory record establishes that Parallel Robotics may market MediBot for its cleared use. It does not establish lower pricing, clinical superiority or commercial adoption.

FlexDex has been used in thousands of procedures across more than a dozen countries, according to Michigan Engineering, providing a record of prior clinical use for Awtar's handheld approach. FlexDex also raised a Series A and a $5 million Series B by 2016, according to U-M Innovation Partnerships.

Parallel Robotics is a separate vehicle for the next iteration of that thesis. University records date Parallel Robotics LLC to 2020, while the SEC filing says Parallel Robotics incorporated in Delaware in 2026.

The offering includes converted promissory notes

The Form D says the offering includes preferred shares issued upon conversion of $6.31 million in promissory notes. The first sale occurred on August 28th, about three weeks before Parallel Robotics filed the notice.

Parallel Robotics reported 32 investors and a $250,000 minimum investment for outside investors. The filing does not name those investors, identify a lead or disclose a valuation. It classifies the securities as equity and states that the offering remains open.

University of Michigan records add another layer to the capitalization. In February, the university approved a worldwide exclusive license covering patents and technical information for an enhanced-dexterity surgical tool and a transmission system for snake-style, multi-link end effectors. Under the license agreement, Parallel Robotics agreed to pay royalties and reimburse patent expenses, while the university received equity and retained a right to buy additional shares.

On May 21st, the University of Michigan Board of Regents approved potential investment agreements with Parallel Robotics under the Accelerate Blue Fund or similar Innovation Partnerships-managed funds. The May 21st Board agenda says those funds had no obligation to invest, and the approval does not establish that a university-managed fund participated in this offering.

Parallel Robotics has also received $305,000 through an NSF Phase I award to build and test pre-clinical prototypes of a surgical manipulator combining human power, computer control and wrist-based articulation. The federal award describes testing with surgeons in simulated environments, pointing to a broader platform beyond the cleared needle driver.

The financing arrives after Awtar has assembled the pieces that university medical-device spinouts often tackle separately: licensed intellectual property, an FDA-cleared product, federal research funding and a founder with prior commercialization experience. The next test is distribution. Parallel Robotics still has to establish pricing, manufacturing economics, surgeon adoption and whether a powered handheld instrument can earn a regular place in operating rooms already stocked with conventional tools and large robotic systems.

Awtar's record gives Parallel Robotics a credible starting point. FlexDex moved an articulated surgical instrument from a university workbench into thousands of clinical procedures, according to U-M. MediBot carries a more ambitious combination of mechanics, electronics and software. The $7.31 million in securities sold gives Parallel Robotics room to test whether the added control can preserve the cost and workflow advantages that made Awtar's first surgical device useful.